These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22863719)

  • 1. Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases.
    Shen H; Xia L; Lu J
    Cytokine; 2012 Nov; 60(2):334-7. PubMed ID: 22863719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.
    Yuan L; Yao L; Zhao L; Xia L; Shen H; Lu J
    Clin Exp Rheumatol; 2013; 31(3):428-32. PubMed ID: 23485578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
    Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
    Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.
    Jiang Q; Li Y; Xia L; Shen H; Lu J
    J Interferon Cytokine Res; 2019 Nov; 39(11):720-725. PubMed ID: 31274382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis.
    Kawasumi H; Gono T; Kawaguchi Y; Kaneko H; Katsumata Y; Hanaoka M; Kataoka S; Yamanaka H
    Biomed Res Int; 2014; 2014():815245. PubMed ID: 24800252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
    Chen F; Shu XM; Wang DX; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.
    Liu T; Hou Y; Dai TJ; Yan CZ
    Chin Med J (Engl); 2017 Sep; 130(17):2101-2106. PubMed ID: 28836555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
    Shu X; Peng Q; Lu X; Wang G
    PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.
    Li T; Tang ZY; Zhang QB; Xiao FN; Jian GL; Xie Y; Guo JW; Qing YF
    Curr Rheumatol Rev; 2023; 19(4):455-462. PubMed ID: 37005523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
    Kubo M; Ihn H; Yamane K; Kikuchi K; Yazawa N; Soma Y; Tamaki K
    Rheumatology (Oxford); 2000 Jun; 39(6):632-6. PubMed ID: 10888708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease.
    Takada T; Suzuki E; Nakano M; Kagamu H; Tsukada H; Hasegawa T; Satoh M; Haraguchi M; Ebe T; Arakawa M
    Intern Med; 1998 Aug; 37(8):669-73. PubMed ID: 9745852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.
    Son K; Tomita Y; Shimizu T; Nishinarita S; Sawada S; Horie T
    Intern Med; 2000 Feb; 39(2):128-35. PubMed ID: 10732829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.
    Lou Y; Zheng Y; Fan B; Zhang L; Zhu F; Wang X; Chen Z; Tan X; Wei Q
    BMC Pulm Med; 2020 Jul; 20(1):196. PubMed ID: 32680574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.